triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study#912398ClinicalTrials.gov
• 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)#18622ClinicalTrials.gov
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer#890974ClinicalTrials.gov
• Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer#28316ClinicalTrials.gov
• Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer#910104ClinicalTrials.gov
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer#803486ClinicalTrials.gov
• Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy#861074ClinicalTrials.gov
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer#807055ClinicalTrials.gov
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases#442105ClinicalTrials.gov
• Exercise in Triple- Negative Breast Cancer#268004ClinicalTrials.gov
• The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer#800289ClinicalTrials.gov
• Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial#1031502ClinicalTrials.gov
• Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer#18583ClinicalTrials.gov
• Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy#181759ClinicalTrials.gov
• Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer#864678ClinicalTrials.gov
• ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer#878385ClinicalTrials.gov
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer#884216ClinicalTrials.gov
• A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)#835459ClinicalTrials.gov
• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations#803346ClinicalTrials.gov
• Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer#208449ClinicalTrials.gov
• Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer#841843ClinicalTrials.gov
• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery#383568ClinicalTrials.gov
• A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer#835795ClinicalTrials.gov
• Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer#885276ClinicalTrials.gov
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).#373604ClinicalTrials.gov
• Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer#387158ClinicalTrials.gov
• BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer#862427ClinicalTrials.gov
• Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer#868605ClinicalTrials.gov
• Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer#873047ClinicalTrials.gov
• Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab#217005ClinicalTrials.gov
• ImmunoBreast - A Phase Ib Study#424188ClinicalTrials.gov
• A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer#968509ClinicalTrials.gov
• Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.#836341ClinicalTrials.gov
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer#874880ClinicalTrials.gov
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer#174862ClinicalTrials.gov
• Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer#429663ClinicalTrials.gov
• Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer#810883ClinicalTrials.gov
• Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)#838340ClinicalTrials.gov
• Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer#870729ClinicalTrials.gov
• Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer#913216ClinicalTrials.gov
• Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer#850916ClinicalTrials.gov
• A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer#879817ClinicalTrials.gov
• Assessment of Candidate Protein Expression in Breast Cancer Specimens#839684ClinicalTrials.gov
• NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer#880323ClinicalTrials.gov
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors#810907ClinicalTrials.gov
• Study of Erlotinib and Metformin in Triple Negative Breast Cancer#234380ClinicalTrials.gov
• FMT in Triple Negative Breast Cancer Guided by ctDNA#390934ClinicalTrials.gov
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer#463722ClinicalTrials.gov
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer#863858ClinicalTrials.gov
• Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK#300243ClinicalTrials.gov